Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | ALDH3A1 | P30838 | 6/20 | 0.64 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.64 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830744 | 0.93 | ALDH1A1 (0.55) | ALDH1A1ALDH3A1ALDH2CCKBRKMT2A | |
| SCHEMBL17830745 | 0.92 | ALDH1A1 (0.56) | ALDH1A1ALDH3A1ALDH2KMT2AMAPT | |
| SCHEMBL17830746 | 0.88 | ALDH1A1 (0.51) | ALDH1A1ALDH3A1ALDH2PARK7 | |
| SCHEMBL17830742 | 0.88 | ALDH1A1 (0.63) | ALDH1A1ALDH3A1ALDH2KMT2APOLB | |
| SCHEMBL17830751 | 0.88 | ALDH1A1 (0.51) | ALDH1A1ALDH3A1ALDH2CCKBRKMT2A | |
| SCHEMBL17830747 | 0.88 | ALDH1A1 (0.52) | ALDH1A1ALDH3A1ALDH2KMT2APARK7 | |
| SCHEMBL17830743 | 0.88 | ALDH1A1 (0.60) | ALDH1A1ALDH3A1ALDH2KMT2APOLB | |
| SCHEMBL17830752 | 0.87 | ALDH1A1 (0.51) | ALDH1A1ALDH3A1ALDH2CCKBRKMT2A | |
| SCHEMBL17830740 | 0.86 | ALDH1A1 (0.52) | ALDH1A1ALDH3A1ALDH2KMT2APARK7 | |
| SCHEMBL17830741 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ALDH3A1ALDH2PARK7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | ALDH1A1 4832/4885ALDH3A1 4762/4885ALDH2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.